Kamada (KMDA) Revenue (2012 - 2026)
Kamada's (KMDA) quarterly Revenue came in at $54.9 million in Q2 2026, up 22.72% on a YoY basis from $44.8 million in Q2 2025, and up 21.4% quarter-over-quarter from $45.2 million in Q1 2026.
Analysis
Kamada (KMDA) Revenue (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Revenue for 15 consecutive years, with $54.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Revenue rose 22.72% year-over-year to $54.9 million; the trailing twelve-month figure through Jun 2026 stood at $191.8 million (up 13.17% YoY), and the FY2025 full-year result was $180.5 million, up 12.12% from the prior year.
- Revenue climbed to $54.9 million in Q2 2026 per KMDA's latest filing, from $45.2 million in the prior quarter.
- Across five years, Revenue topped out at $54.9 million in Q2 2026 and bottomed at $23.6 million in Q2 2022.
- Historically, Revenue has averaged $39.6 million across 5 years, with a median of $40.4 million in 2024.
- The widest YoY moves for Revenue: up 58.72% in 2023, down 19.82% in 2023.
- Over 5 years, Revenue stood at $45.4 million in 2022, then dropped by 19.82% to $36.4 million in 2023, then gained by 7.06% to $39.0 million in 2024, then increased by 14.54% to $44.7 million in 2025, then rose by 22.93% to $54.9 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $54.9 million, $45.2 million, and $44.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 210.97 Bn | 196.98 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 180.98 Bn | 177.80 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 132.09 Bn | 124.24 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.57 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 61.71 Bn | 56.53 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 54.60 Bn | 49.46 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.02 Bn | 30.71 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Roivant Sciences | 29.76 Bn | 29.76 Bn | 1.16 Mn | 1.44 Mn |
| 10 | Kamada | 473.28 Mn | 403.14 Mn | 22.47 Mn | 54.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 54.92 Mn |
| Mar 31, 2026 | 45.24 Mn |
| Dec 31, 2025 | 44.68 Mn |
| Sep 30, 2025 | 47.01 Mn |
| Jun 30, 2025 | 44.75 Mn |
| Mar 31, 2025 | 44.02 Mn |
| Dec 31, 2024 | 39.01 Mn |
| Sep 30, 2024 | 41.74 Mn |
| Jun 30, 2024 | 42.47 Mn |
| Mar 31, 2024 | 37.74 Mn |
| Dec 31, 2023 | 36.43 Mn |
| Sep 30, 2023 | 37.93 Mn |
| Jun 30, 2023 | 37.44 Mn |
| Mar 31, 2023 | 30.71 Mn |
| Dec 31, 2022 | 45.44 Mn |
| Sep 30, 2022 | 32.22 Mn |
| Jun 30, 2022 | 23.59 Mn |
| Mar 31, 2022 | 28.09 Mn |
| Dec 31, 2021 | 31.47 Mn |
| Sep 30, 2021 | 23.03 Mn |